| Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide S Walpole, AL Pritchard, CM Cebulla, R Pilarski, M Stautberg, ... JNCI: Journal of the National Cancer Institute 110 (12), 1328-1341, 2018 | 220 | 2018 |
| Profiling of genes expressed in peripheral blood mononuclear cells predicts glucocorticoid sensitivity in asthma patients H Hakonarson, US Bjornsdottir, E Halapi, J Bradfield, F Zink, M Mouy, ... Proceedings of the National Academy of Sciences 102 (41), 14789-14794, 2005 | 209 | 2005 |
| TGF-β signaling–deficient hematopoietic stem cells have normal self-renewal and regenerative ability in vivo despite increased proliferative capacity in vitro J Larsson, U Blank, H Helgadottir, JM Björnsson, M Ehinger, ... Blood 102 (9), 3129-3135, 2003 | 192 | 2003 |
| Tie2Cre-mediated gene ablation defines the stem-cell leukemia gene (SCL/tal1)–dependent window during hematopoietic stem-cell development TM Schlaeger, HKA Mikkola, C Gekas, HB Helgadottir, SH Orkin Blood 105 (10), 3871-3874, 2005 | 128 | 2005 |
| The genetics of uveal melanoma: current insights H Helgadottir, V Höiom The application of clinical genetics, 147-155, 2016 | 126 | 2016 |
| Sequencing of ipilimumab plus nivolumab and encorafenib plus binimetinib for untreated BRAF-mutated metastatic melanoma (SECOMBIT): a randomized, three-arm, open-label phase II … PA Ascierto, M Mandalà, PF Ferrucci, M Guidoboni, P Rutkowski, ... Journal of Clinical Oncology 41 (2), 212-221, 2023 | 113 | 2023 |
| High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families H Helgadottir, V Höiom, G Jönsson, R Tuominen, C Ingvar, Å Borg, ... Journal of medical genetics 51 (8), 545-552, 2014 | 111 | 2014 |
| The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma L Ny, H Jespersen, J Karlsson, S Alsén, S Filges, C All-Eriksson, ... Nature communications 12 (1), 5155, 2021 | 103 | 2021 |
| Hereditary uveal melanoma: A report of a germline mutation in BAP1 V Höiom, D Edsgärd, H Helgadottir, H Eriksson, C All‐Ericsson, ... Genes, Chromosomes and Cancer 52 (4), 378-384, 2013 | 72 | 2013 |
| Germline CDKN2A Mutation Status and Survival in Familial Melanoma Cases H Helgadottir, V Höiom, R Tuominen, K Nielsen, G Jönsson, H Olsson, ... Journal of the national Cancer Institute 108 (11), djw135, 2016 | 69 | 2016 |
| Mef2C is a lineage-restricted target of Scl/Tal1 and regulates megakaryopoiesis and B-cell homeostasis C Gekas, KE Rhodes, LM Gereige, H Helgadottir, R Ferrari, SK Kurdistani, ... Blood, The Journal of the American Society of Hematology 113 (15), 3461-3471, 2009 | 62 | 2009 |
| Personalized medicine in malignant melanoma: towards patient tailored treatment H Helgadottir, I Rocha Trocoli Drakensjö, A Girnita Frontiers in oncology 8, 202, 2018 | 56 | 2018 |
| Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma H Helgadottir, L Kis, P Ljungman, J Larkin, R Kefford, PA Ascierto, ... Annals of Oncology 28 (7), 1672-1673, 2017 | 55 | 2017 |
| Lentivirus gene transfer in murine hematopoietic progenitor cells is compromised by a delay in proviral integration and results in transduction mosaicism and heterogeneous gene … H Mikkola, NB Woods, M Sjögren, H Helgadottir, I Hamaguchi, ... Journal of Virology 74 (24), 11911-11918, 2000 | 54 | 2000 |
| Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study H Jespersen, R Olofsson Bagge, G Ullenhag, A Carneiro, H Helgadottir, ... BMC cancer 19, 1-7, 2019 | 50 | 2019 |
| Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations H Helgadottir, P Ghiorzo, R Van Doorn, S Puig, M Levin, R Kefford, ... Journal of medical genetics 57 (5), 316-321, 2020 | 47 | 2020 |
| Cancer risks and survival in patients with multiple primary melanomas: Association with family history of melanoma and germline CDKN2A mutation status H Helgadottir, R Tuominen, H Olsson, J Hansson, V Höiom Journal of the American Academy of Dermatology 77 (5), 893-901, 2017 | 43 | 2017 |
| LBA45 First report of efficacy and safety from the phase II study SECOMBIT (SEquential COMBo Immuno and Targeted therapy study) PA Ascierto, M Mandala, PF Ferrucci, P Rutkowski, M Guidoboni, ... Annals of Oncology 31, S1173-S1174, 2020 | 42 | 2020 |
| LBA40 SECOMBIT: The best sequential approach with combo immunotherapy [ipilimumab (I)/nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with … PA Ascierto, M Mandala, PF Ferrucci, P Rutkowski, M Guidoboni, ... Annals of Oncology 32, S1316-S1317, 2021 | 33 | 2021 |
| CDKN2a mutation‐negative melanoma families have increased risk exclusively for skin cancers but not for other malignancies H Helgadottir, V Höiom, R Tuominen, G Jönsson, E Månsson‐Brahme, ... International journal of cancer 137 (9), 2220-2226, 2015 | 33 | 2015 |
Gustav Ullenhag在 igp.uu.se 的电子邮件经过验证
